Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
CN Stock MarketDetailed Quotes
002793 Luoxin Pharmaceuticals Group Stock
- 4.72
- +0.43+10.02%
Market Closed Apr 24 15:00 CST
5.13BMarket Cap-5.56P/E (TTM)
4.72High4.30Low584.46KlotVolume4.30Open4.29Pre Close270.46MTurnover5.38%Turnover RatioLossP/E (Static)1.09BShares5.3252wk High3.68P/B5.13BFloat Cap3.2252wk Low4.72Limit Up1.09BShs Float27.94Historical High3.86Limit Down9.79%Amplitude3.22Historical Low--Dividend TTM4.63Avg Price285.88KlotAsk--Div YieldTTM100Lot Size283.76KlotBid
About Luoxin Pharmaceuticals Group Stock Company
The company was founded in 1988. Adhering to the corporate mission of “delivering health”, the company takes scientific and technological innovation as its mission, focuses on unmet clinical needs, and is committed to providing patients around the world with more innovative drug choices. The company entered the A-share market in 2020 and has continuously entered the top 100 Chinese pharmaceutical industry enterprises since 2006. The company is mainly engaged in R&D, production and sales of pharmaceutical products, focusing on superior fields such as digestion, respiration, and anti-tumor. The company's main products: tigolacin tablets, meropenem for injection, omeprazole enteric capsules, cefuroxime sodium for injections, cefumezole sodium for injections, clindamycin phosphate for injections, glutathione for injections, ambroxol hydrochloride for injections, rabeprazole sodium for injections, etc. Company honors: The company has been on the “Top 100 Chinese Pharmaceutical Companies List” for 17 consecutive years, the “Most Influential Chinese Pharmaceutical Industry List” for 10 consecutive years, won the “China Pharmaceutical Research and Development Product Line Best Industrial Enterprise” award for 13 consecutive years, and the “Top 20 Innovative Pharmaceutical Enterprises in China” for 5 consecutive years. During the reporting period, it won “China Pharmaceutical Independent Innovation Pioneer Enterprise”, “China Pharmaceutical Industry Law-abiding and Honest Enterprise”, “Shandong Province's 2023 First Batch of Innovative Small and Medium Enterprises”, “Shandong Province's 2023 Specialized and Special New Small and Medium Enterprises”, Zhejiang Famous Brand Products, Advanced Unit for “Honest and Law-abiding Enterprise” activities, 2014 Top Ten Industrial Enterprises, Contract-abiding and Credit-abiding AA, etc.
Company Profile
Short Name-A罗欣药业
Symbol-A002793
Company NameLuoxin Pharmaceuticals Group Stock Co., Ltd.
Listing DateApr 15, 2016
Issue Price11.97
Shares Offered25.00M share(s)
FoundedMay 11, 1998
Listed ExchangeSZ Stock Exchange
Legal Representativezhenteng liu
General Managerzhenteng liu
Secretaryfengsheng han
Accounting FirmTianjian Certified Public Accountants (Special General Partnership)
Securities Representativejianhua wang
Legal CounselBeijing King & Wood Mallesons Shanghai Branch
Phone021-38867666
Office AddressBuilding 4, No. 18 Luoqi Road, Luozhuang District, Linyi City, Shandong Province
Zip Code276017
Registered AddressBuilding 4, No. 18 Luoqi Road, Luozhuang District, Linyi City, Shandong Province
Fax021-38867600
EmailIR@luoxin.cn
Websitehttp://www.luoxin.cn
Business License331081100011767
BusinessGeneral projects: Class I medical device production; Class I medical device wholesale; Class II medical device retail; Class II medical device retail; Class I medical device retail; medical research and experimental development; technical services, technology development, technical consultation, technical exchange, technology transfer, technology promotion (except for projects subject to approval according to law, independently carry out business activities with a business license in accordance with law). License projects: Class II medical device production; Class III medical device production; Class III medical device management; pharmaceutical production; drug contract manufacturing; drug wholesale; drug import/export; drug retail; technology import/export (projects requiring approval according to law can only be carried out business activities after approval by relevant departments; specific business projects are subject to approval by relevant departments). (Subject to the scope of business approved by the company registration authority).
Company Executives
- Name
- Position
- Salary
- zhenteng liu
- Chairman, Directors, General Manager, Nomination Committee Members, Member of the Remuneration and Assessment Committee, Chairman of the Strategy Committee
- 1.87M
- zhenfei liu
- Directors, Strategy Committee Member, Audit Committee Member
- 1.68M
- zhiang wu
- Independent Directors, Member of the Remuneration and Assessment Committee, Chairman of the Nomination Committee
- 98.40K
- xia xu
- Independent Directors, Nomination Committee Members, Chairman of the Audit Committee
- 98.40K
- yunpei guo
- Independent Directors, Chairman of the Remuneration and Assessment Committee, Audit Committee Member
- 98.40K
- fengsheng han
- Board Secretary
- 845.70K
- jianhua wang
- Securities Affairs Representative
- --
- liangwei song
- Chairman of the Supervisory Board, Employee Supervisors
- 982.50K
- fang xia
- Auditors
- --
- xiaotong zhu
- Deputy General Manager
- 2.42M
- xian chen
- Head of Finance
- 2.21M
- fei gao
- Head of an Internal Audit Agency
- --
- lili song
- Employee Supervisors
- 346.70K
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 9 20:29
Learning From Buffett: Investing Wisely Amid Market Volatility Triggered by Trump's Tariffs